The Retatrutide vs Amycretin comparison explores another novel amylin-based approach, while the Retatrutide vs Orforglipron analysis examines oral GLP-1 receptor agonists
Patients often report diminished appetite, earlier meal satiety, decreased cravings, enhanced physical energy, and improved vital health indicators
So far, three major problems have kept GLP-1 drugs injectable rather than oral: enzymatic degradation, poor bioavailability, and the sheer cost of manufacturing
Similarly, trials examining the reverse scenarioadding a GLP-1 agonist to DPP-4 inhibitor therapyhave shown that whilst some glycaemic improvement occurs, it is primarily attributable to the GLP-1 agonist itself, with the DPP-4 inhibitor contributing minimally
However, clinical data in humans remains limited
At 272 pounds, I struggled with anxiety, depression, and sleep apnea